In 2023, Zhejiang Jiuzhou Pharmaceutical completed a corporate carbon footprint assessment and publicly disclosed its greenhouse gas (GHG) emissions according to the GHG Protocol, covering Scope 1 (direct emissions from owned or controlled sources), Scope 2 (indirect emissions from purchased energy), and Scope 3 (indirect emissions across the value chain).
However, Zhejiang Jiuzhou Pharmaceutical has not published a category-level breakdown of its Scope 3 emissions, limiting visibility into specific value chain sources.
Metric (tCO2e) | 2024 | 2023 | 2022 | 2021 - 2017 |
---|---|---|---|---|
Total Scope 1 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 2 | ||||
Unspecified Calculation Method | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
Total Scope 3 | 0000000 | Copy restricted. Please purchase to unlock this data. | Copy restricted. Please purchase to unlock this data. | 0000000 |
This table provides a simplified preview of selected GHG emissions data points. To access the complete dataset with full disclosures, detailed breakdowns, and source traceability, create a free account to view purchase options.
In 2023, the total operational greenhouse gas (GHG) emissions of Zhejiang Jiuzhou Pharmaceutical amounted to 300,761.29 metric tons of CO2 equivalent. This figure includes both direct emissions from owned or controlled sources (Scope 1) and indirect emissions from purchased energy (Scope 2).
Compared to 2022, the total operational greenhouse gas (GHG) emissions of Zhejiang Jiuzhou Pharmaceutical increased by 45.74%, suggesting that the company faced challenges in reducing its emissions from its core operations.
In 2023, the total Scope 1 emissions of Zhejiang Jiuzhou Pharmaceutical were 48,815.1 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
Since 2021, Zhejiang Jiuzhou Pharmaceutical's Scope 1 emissions have increased by 1,021.62%, reflecting a rising long-term trend in Scope 1 emissions over time.
Compared to the previous year (2022), Zhejiang Jiuzhou Pharmaceutical's Scope 1 emissions increased by 956.23%, suggesting that the company faced challenges in reducing emissions from its directly owned or controlled operations.
In 2023, Zhejiang Jiuzhou Pharmaceutical reported Scope 2 greenhouse gas (GHG) emissions of 251,946.19 tCOâ‚‚e without specifying the calculation method.
Since 2021, Zhejiang Jiuzhou Pharmaceutical's Scope 2 greenhouse gas (GHG) emissions (Unspecified Calculation Method) have increased by 42.15%, reflecting a rising long-term trend in Scope 2 emissions over time.
Compared to the previous year (2022), Zhejiang Jiuzhou Pharmaceutical's Scope 2 emissions (Unspecified Calculation Method) rose by 24.88% in 2023, suggesting that the company faced challenges in reducing emissions from purchased electricity and energy
In 2023, Zhejiang Jiuzhou Pharmaceutical reported its Scope 2 emissions using an unspecified methodology.
In 2023, Zhejiang Jiuzhou Pharmaceutical reported 6,914,788.17 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) of Scope 3 greenhouse gas (GHG) emissions, representing indirect emissions across its upstream and downstream value chain.
The 2023 disclosure of Zhejiang Jiuzhou Pharmaceutical includes a breakdown across 0 of the 15 Scope 3 categories defined by the GHG Protocol, matching the level of disclosure in 2022, demonstrating consistent Scope 3 emissions reporting coverage year over year.
In 2023, Zhejiang Jiuzhou Pharmaceutical reported total Scope 3 emissions of 6,914,788.17 metric tons of COâ‚‚ equivalent (tCOâ‚‚e).
In 2023, Zhejiang Jiuzhou Pharmaceutical reported a total carbon footprint of 7,215,549.46 metric tons of COâ‚‚ equivalent (tCOâ‚‚e) across Scope 1, Scope 2, and Scope 3 emissions. This represents a 3,396.45% increase compared to 2022, suggesting a rise in emissions across its operations or value chain.
The largest contributor to Zhejiang Jiuzhou Pharmaceutical's total carbon footprint was Scope 3 emissions, accounting for 95.83% of the company's total carbon footprint, followed by Scope 2 emissions at 3.49%.